𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial

✍ Scribed by Valerio Nobili; Melania Manco; Rita Devito; Vincenzo Di Ciommo; Donatella Comparcola; Maria Rita Sartorelli; Fiorella Piemonte; Matilde Marcellini; Paul Angulo


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
212 KB
Volume
48
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


No proven treatment exists for nonalcoholic fatty liver disease (NAFLD) in children and adolescents. We sought to determine the efficacy of lifestyle intervention with or without antioxidant therapy in pediatric NAFLD. A total of 53 patients (age 5.7-18.8 years, 37 boys) were included. Lifestyle intervention consisting of a diet tailored to the patient's calorie needs, and increased physical activity was prescribed in all. Patients were concomitantly randomized to alpha-tocopherol 600 IU/day plus ascorbic acid 500 mg/day (n ‫؍‬ 25) or placebo (n ‫؍‬ 28), and treated for 24 months. The study was an extension of a previous study aimed at evaluating the effect of 12-month lifestyle intervention and antioxidant therapy on serum levels of aminotransferases. The primary end point of the present study was change in liver histology on repeated biopsy at 24 months. Secondary end points were changes in body weight, liver enzymes, and insulin sensitivity indices on 2-hour oral glucose tolerance test. The amount of weight lost at 24 months was similar in the placebo and antioxidant groups (؊4.75 [range, ؊16-4.0] versus ؊5.5 [range, ؊12.2-0.4] kg, respectively, P ‫؍‬ 0.9). A significant improvement occurred in the grade of steatosis, lobular inflammation, and hepatocyte ballooning, and in the NAFLD activity score in both groups. Levels of aminotransferases, triglycerides, cholesterol, fasting glucose, and insulin, and insulin sensitivity indices improved significantly as well. The improvement in all these parameters was not significantly different between the two groups. Conclusion: Lifestyle intervention with diet and increased physical activity induces weight loss and is associated with a significant improvement in liver histology and laboratory abnormalities in pediatric NAFLD. Alpha-tocopherol plus ascorbic acid does not seem to increase the efficacy of lifestyle intervention alone. (HEPATOLOGY 2008; 48:119-128.)

N onalcoholic fatty liver disease (NAFLD) is rapidly becoming one of the most important chronic liver diseases in children and adolescents. NAFLD affects 2.6% to 9.8% of children and ad-


πŸ“œ SIMILAR VOLUMES


Betaine for nonalcoholic fatty liver dis
✍ Manal F. Abdelmalek; Schuyler O. Sanderson; Paul Angulo; Consuelo Soldevila-Pico πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 227 KB πŸ‘ 2 views

Based on animal studies and pilot studies in humans, betaine, a methyl donor for the remethylation of homocysteine, may be a therapeutic agent for nonalcoholic steatohepatitis (NASH). We evaluated the safety and efficacy of betaine for patients with NASH and whether betaine positively modified facto

Correction: Betaine for nonalcoholic fat
✍ Manal F. Abdelmalek; Schuyler O. Sanderson; Paul Angulo; Consuelo Soldevila-Pico πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 46 KB πŸ‘ 2 views

Data describing cirrhosis prevalence in the simple steatosis group reported in the study by Rafiq et al. should read NR (not reported) instead of 42 (56.8%). All cirrhosis prevalence proportions were calculated based upon these correct (NR) data.

Outpatient, sequential, parenteral-oral
✍ Hugo Paganini; Sandra GΓ³mez; Silvina Ruvinsky; Pedro Zubizarreta; Antonio Latell πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 81 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Recent reports and previous randomized trials conducted at the authors' institution suggested that children with lower risk febrile neutropenic (LRFN) may benefit from substitution of oral antibiotic therapy for parenteral therapy. The objective of this study was to deter

Efficacy and safety of high-dose pravast
✍ James H. Lewis; Mary Ellen Mortensen; Steven Zweig; Mary Jean Fusco; Jeffrey R. πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 148 KB πŸ‘ 1 views

The hepatotoxic potential of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in patients with underlying chronic liver disease remains controversial. We performed a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that compared pravastatin (80 mg) to a place